, yielding thymidine diphosphate (dTDP) and ADP. 3 Because TMPK is essential for thymidine triphosphate (dTTP) synthesis and in view of its low (22%) sequence identity with the human isozyme (TMPKh), 2 it represents an attractive target for selectively inhibiting mycobacterial DNA synthesis. Recently, the X-ray structure of TMPKmt was solved at 1.95Å as a complex with dTMP, 4 allowing structure-based design of TMPKmt ligands.
A series of 2'-, 3'-and 5-modified nucleosides and nucleotides was tested for their affinities with respect to TMPKmt. 5, 6, 7, 8 The results showed that, in general, nucleosides and their corresponding 5'-O-monophosphate esters were nearly equivalent inhibitors of TMPKmt. The low permeability of the cell wall for phosphorylated compounds (i.e. nucleotides) prompted us to focus on nucleosides as new drug leads. Recently, we reported a series of 3'-C-branched chain nucleosides and nucleotides that exhibit micromolar inhibitory activity against TMPKmt. 9 The introduction of 3'-CH 2 OH, 3'-CH 2 NH 2 , 3'-CH 2 N 3 and 3'-CH 2 F substituents was aimed at occupying a cavity in the enzyme near the 3'-position. Biological results and modeling confirmed this hypothesis. Modeling also indicated that these nucleosides bind to TMPKmt in the (N) (northern, 2'-exo-3'-endo) conformation dTMP, in contrast, binds to TMPKmt in the (S) (southern, 2'-endo, 3'-exo) conformation. This N-type sugar pucker enables interactions between the 6'-substituent and Asp9. 9 From this series of 3'-branched chain derivatives, 1-3-C-(azidomethyl)-2,3-dideoxy--D-threo-pentofuranosylthymine (1) emerged as a promising lead for further research, since it combines a low K i -value with a favourable selectivity profile for TMPKmt versus TMPKh (Table 1) . Moreover, conformational analysis of a series of 2'-and 3'-modified nucleosides showed that the presence of a halogen at the -face of the 2'-position, especially a 2'-fluorine, biases the sugar pucker of thymidine analogues strongly towards the (N) conformation. 10 Based on these results and the high affinities of 2'-halogeno substituted nucleotides for TMPKmt 5 (3 and 4, Table 1 ), it was considered interesting to combine a 2'-chlorine or a 2'-fluorine substituent with a 3'-aminomethyl or a 3'-azidomethyl group (5-8).
9
In an attempt to supersede the good affinities of the 3'-C-branched-chain nucleosides, we also further explored the enzyme cavity near the 3'-position with alternative nitrogen containing substituents.
Results and Discussion

Chemistry
The synthesis of 5-9 started from 14 (obtained from 1,2-O-isopropylidene--D-xylofuranose in 11 steps 11 ) (Scheme 1). After protection of the 5'-hydroxyl group, 15 was converted into anhydronucleoside 16 upon treatment with trifluoromethanesulfonyl chloride and DMAP.
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Opening of the anhydro ring with HCl in dioxane yielded 5, the 2'--chloro analogue of 1.
13
The corresponding 2'-fluoro derivative 7 was obtained via formation of ara-nucleoside 17 from 16 with NaOH, 14 followed by fluorination with DAST 15 and removal of the trityl protective group. Reduction of 5 and 7 with Ph 3 P and NH 3 yielded the corresponding 3'-amino analogues 6 and 8, respectively. with DAST afforded 9 in low yield.
In an attempt to prepare intermediate 20 for further derivatisation, the 5'-hydroxyl group of 14 was first protected as t-butyldimethylsilyl ether 18 (Scheme 2). After esterification of the 2'-hydroxyl with phenylchlorothionocarbonate (→19), 11 however, attempted simultaneous reduction of the azido function and Barton deoxygenation at the 2'-position to give 20 failed.
Biological activity
All nucleosides were tested for their affinity for TMPKmt (Table 1 ) via a reported spectrometric assay. 21 The affinities of most 2'-halo substitued nucleosides were not as expected. In 5-8, the introduction of the 2'-halogen led to a drastic decrease in affinity compared to the corresponding 2'-deoxynucleosides. Due to the presence of the 2'-fluorine, 8
showed no inhibition of the enzyme at 1 mM . Docking suggested that instead of enhancing the (N) conformation, necessary for optimal interaction between Asp9 and the 3'-substituent, the 2'-halogens compete with the 3'-substituents for the same binding pocket, 5 thereby abolishing the affinity for the enzyme. Remarkably, introduction of a 5'-fluorine slightly increases the affinity of 7 (K i of 9 = 80 M).
Compounds 10, 11 and 12 were, likewise, assayed for their affinity for TMPKmt.
Unexpectedly, these compounds are among the highest affinity inhibitors for TMPKmt found so far. Due to the lack of a binding site for a second nucleoside at the 3'-position, the K i -value of 12 (37 M) was most unexpected. A modeling experiment in GOLD showed that the sugar ring of the first monomer I binds the dTMP-pocket upside down, which enables hydrogen bonding of its 5'-hydroxyl with Asp9 ( Figure 1 The six-membered ring, fused to the the C-2', C-3'-bond of the sugar, apparently forces the 6'-nitrogen into the most appropriate position for interaction with the Asp9 residue in the enzyme cavity. The sulphur atom, in its turn, undergoes hydrophobic interactions with Tyr103 and Tyr165 residues. When the sulphur atom in 10 is replaced by a smaller oxygen in 11, the cavity near the 3'-position is filled less efficiently, which is reflected in the somewhat lower affinity of 11. The functionalities of the extra ring convincingly contribute to the high affinity interactions with the biological target.
The highest affinity inhibitors of this series were tested for their affinity for TMPKh. The low affinities of 12 and 13 for the human enzyme indicate that the flexibility towards the orientation of the sugar ring is unique for TMPKmt. Most interesting, however, is compound did not show any significant inhibition of M. tuberculosis at a concentration of 6.25 g/ml. This is not surprising since this concentration is lower then the K i -values of these inhibitors for TMPKmt. Therefore, inhibitors with superior K i -values are indispensable to provide novel antimycobacterial leads.
The discovery of the bicyclic analogues 10 and 11 is an important step towards this goal.
Conclusions
In inhibitor design the binding pocket of the nucleoside in nucleoside and nucleotide metabolizing enzymes is generally explored by introducing small modifications to the substrate. In the present example, however, a variety of sugar modified thymidine analogues have been discovered with apparently different binding modes to TMPKmt involving Asp9, Tyr103 and Phe70 as common amino acids to anchor the inhibitors. These molecules may function as leads for further drug design, increasing considerably the variety of nucleoside analogues that may be considered for further synthesis. Of particular importance is the bicyclic nucleoside 10 with a K i for TMPKmt of 3.5 M and a SI of 200, which will be used as starting compound to increase further affinity for TMPKmt.
Experimental Section
(1) Spectrophotometric binding assay.
TMPKmt and TMPKh activities were determined using the coupled spectrophotometric assay described by Blondin et al. 21 at 334 nm in an Eppendorf ECOM 6122 photometer. The reaction medium (0.5 mL final volume) contained 50 mM Tris-HCl pH 7.4, 50 mM KCl, 2 mM MgCl 2 , 0.2 mM NADH, 1 mM phosphoenol pyruvate and 2 units each of lactate dehydrogenase, pyruvate kinase and nucleoside diphosphate kinase. The concentrations of ATP and dTMP were kept constant at 0.5 mM and 0.05 mM respectively, whereas the concentrations of analogues varied between 0.1 and 2.5 mM.
(2) Inhibition assay of M. tuberculosis.
The screening was conducted at 6.25 g/ml against Mycobacterium tuberculosis H 37 Rv (ATCC 27294) in BACTEC 12B medium using a broth microdilution assay, the Microplate Assay (MABA).
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(3) Modeling: docking experiments using GOLD.
The X-ray structure published by de la Sierra et al. 4 (pdb entry 1G3U) was used in all docking experiments. Water molecules and sulphate counter ions were removed. The Mg 2+ was considered as being part of the enzyme. Explicit hydrogen atoms were added to the enzyme and inhibitor structures using Reduce. 24 The inhibitor structures 10, 12 and 13 were created using Macromodel 5.0, 25 based on the dTMP substrate from pdb entry 1G3U. Their geometry was optimized in the AM1 force field using Mopac6.0.
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PDB files were then converted to mol2 files using Babel. 27 The position of atom C1' in the dTMP ligand in the pdb file 1G3U
was used as the center of a 20 Å docking sphere. Default settings were used in Gold for all dockings. 28, 29 The structures in the top 50 of the docking scores were retained for visual inspection and comparison with published X-ray structures 1G3U 4 and 1MRN. Anhydrous solvents were obtained as follows: THF was distilled from sodium/benzophenone; pyridine was refluxed overnight over potassium hydroxide and distilled; dichloromethane, dichloroethane and toluene were stored over calcium hydride, refluxed, and distilled; DMF was stored over Linde 4 Å molecular sieves, followed by distillation under reduced pressure. 
1-[3-Azidomethyl-3-deoxy-5-O-trityl--D-ribofuranosylthymine (15
1-(3-Azidomethyl-3-deoxy-5-O-trityl--D-arabinofuranosyl)thymine (17
1-(3-Azidomethyl-2,3-dideoxy-2-fluoro--D-ribofuranosyl)thymine (7)
.
1-(3-Azidomethyl-2,5-difluoro-2,3,5-trideoxy--D-ribofuranosyl)thymine (9).
This compound was synthesized from 7 (66 mg, 0.22 mmol) using the procedure described for the synthesis of 7, to yield 12 mg (18 %) of 9. 
1-[3-(Azidomethyl)-2,3-dideoxy--D-erythro-pentofuranosyl]thymine (13). -Anomer 13
was a minor unreported byproduct from the synthesis of 1. Thymine is oriented at the -side of the sugar ring.
n.i. no inhibition; n.d. not determined FIGURE LEGENDS 
